Condition: Vulvar Atrophy · Vulvovaginal Signs and Symptoms · Genitourinary Syndrome of Menopause · Sponsor: Mucosa Innovations, S.L.
The goal of this clinical trial is to improve the management of Genitourinary syndrome of menopause (GSM) to preliminary assess safety and effectivity of a novel hormone-free mucosa composition (XCMIM20m) applied topically to the vulvovaginal area. Symptoms of vaginal atrophy will be compared before and after 8 weeks of use of the tested gel with the Day-to-Day Impact of Vaginal Aging (DIVA) PROMs questionnaire to assess changes impact of GSM symptoms.
This description comes directly from the study's public registry record.
Jorge Rodríguez-Vilaboa · +34 629 288 597 · jorge.vilaboa@mucosainnovations.com
Always discuss trial participation with your own doctor first.
| Mucosa Innovations S.L. | Madrid, Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06962345